SAN
DIEGO, Sept. 6,
2022 /PRNewswire/ -- Viking Therapeutics, Inc.
("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical
company focused on the development of novel therapies for metabolic
and endocrine disorders, today announced that the company will
participate at two upcoming investor conferences.
Details of the company's participation are as follows:
- H.C. Wainwright 24th Annual Global Investment
Conference
Details: Dr. Lian will deliver a corporate
presentation and Viking management will participate in 1-on-1
meetings
Conference Dates: September 12-14, 2022
Presentation Timing: 12:30 – 1:00 p.m. Eastern
on Wednesday, September 14,
2022
Format: Hybrid conference (in person and
virtual); webcast available
- Morgan Stanley 20th Annual Global Healthcare
Conference
Details: Viking management will participate in
1-on-1 meetings
Conference Dates: September 12-14,
2022
Format: In-person at Sheraton New York Hotel
A live webcast of the H.C. Wainwright presentation may be
accessed via a link on the Viking Therapeutics website in the
Investors & Media section under Webcasts.
Additionally, a replay of the webcast will be available on the
Viking website following the conferences.
About Viking Therapeutics,
Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical
company focused on the development of novel first-in-class or
best-in-class therapies for the treatment of metabolic and
endocrine disorders. Viking's research and development
activities leverage its expertise in metabolism to develop
innovative therapeutics designed to improve patients'
lives. The company's clinical programs include VK2809, a
novel, orally available, small molecule selective thyroid hormone
receptor beta agonist for the potential treatment of lipid and
metabolic disorders, which is currently being evaluated in a
Phase 2b study for the treatment of biopsy-confirmed
non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase
2a trial for the treatment of non-alcoholic fatty liver disease
(NAFLD) and elevated low-density lipoprotein-cholesterol (LDL-C),
patients who received VK2809 demonstrated statistically significant
reductions in LDL-C and liver fat content compared with patients
who received placebo. The company is also developing VK2735, a
novel dual agonist of the glucagon-like peptide 1 (GLP-1) and
glucose-dependent insulinotropic polypeptide (GIP) receptors for
the potential treatment of various metabolic disorders. VK2735 is
currently being evaluated in a Phase 1 clinical trial. In the rare
disease space, the company is developing VK0214, a novel, orally
available, small molecule selective thyroid hormone receptor beta
agonist for the potential treatment of X-linked
adrenoleukodystrophy (X-ALD). VK0214 is currently being
evaluated in a Phase 1b clinical trial in patients with
the adrenomyeloneuropathy (AMN) form of X-ALD.
For more information about Viking Therapeutics, please
visit www.vikingtherapeutics.com. Follow Viking on Twitter
@Viking_VKTX.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-upcoming-investor-conferences-301617281.html
SOURCE Viking Therapeutics, Inc.